PlumX Metrics
Embed PlumX Metrics

Ductal carcinoma in situ: Treatment or active surveillance?

Expert Review of Anticancer Therapy, ISSN: 1744-8328, Vol: 15, Issue: 7, Page: 777-785
2015
  • 20
    Citations
  • 0
    Usage
  • 54
    Captures
  • 1
    Mentions
  • 12
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    20
  • Captures
    54
  • Mentions
    1
    • News Mentions
      1
      • News
        1
  • Social Media
    12
    • Shares, Likes & Comments
      12
      • Facebook
        12

Most Recent News

Why Surgery Isn’t Always Necessary for This Form of Breast Cancer

How could breast cancer treatment be unnecessary? Xray Computer/Shutterstock The thought of a breast cancer diagnosis strikes a chill in the heart of every woman.

Review Description

Ductal carcinoma-in situ (DCIS) is a non-obligate precursor for invasive breast cancer and concern exists regarding the potential for overdiagnosis and overtreatment as the natural history of DCIS progression to invasive breast cancer may never occur or take decades in some cases. Preoperative systemic therapy window studies may provide powerful clues to best uncover which particular DCIS lesions respond to systemic therapies and allow for future selective personalized management recommendations. One of the main challenges for instituting active surveillance for DCIS with vacuum-assisted core needle biopsy alone and no surgery is concern for leaving untreated occult invasive carcinoma. Breast MRI lacks sufficient diagnostic ability to differentiate pure DCIS from invasive cancer with DCIS. Current novel randomized trials investigating active surveillance versus active management are described. Multigene expression assays may someday prove useful in stratifying patients at increased risk for progression to invasive breast cancer in the absence of surgery.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know